Hepatitis B and Hepatitis C Reactivation in the Biologic Era
نویسندگان
چکیده
Hepatitis B (HBV) and hepatitis C (HCV) reactivation may occur after the use of biologic agents. During the last decade, utilization of biologics has changed the fate of many treated for cancer, autoimmune and connective tissue disease, maintenance of transplanted organs, and the prevention of graft-versus-host disease among others. HBV reactivation has been reported in up to 50% of HBV carriers undergoing immunosuppressive therapy, and there is emerging data pointing towards an increased risk for HCV reactivation. If reactivation of HBV and HCV occurs, the spectrum of clinical manifestations can range from asymptomatic hepatitis flares to hepatic decompensation, fulminant hepatic failure, and death. Therefore, identifying patients at risk and early diagnosis are imperative to decrease significant morbidity and mortality. The purpose of this article is to review the pathophysiology of the reactivation of HBV and HCV infection in patients receiving biologic therapies and the approaches used to diagnose, prevent, and treat HBV and HCV reactivation.
منابع مشابه
A Case of Hairy Cell Leukemia Associated with Hepatitis B Surface (HBs) Antigenemia and Concurrent Hepatitis C Virus (HCV) Seropositivity
Literature review shows that hepatitis C infection may increase the risk of non-hodgkin lymphoma. Reactivation of hepatitis B infection has been reported in patients with hairy cell leukemia after chemotherapy and/or splenectomy. We present hepatitis B surface (HBs) antigenemia and concurrent hepatitis C virus (HCV) seropositivity in a case of hairy cell leukemia. Key Words: Hairy cell leukemi...
متن کاملCurrent trends in management of hepatitis B virus reactivation in the biologic therapy era.
Hepatitis B virus (HBV) reactivation represents an emerging cause of liver disease in patients undergoing treatment with biologic agents. In particular, the risk of HBV reactivation is heightened by the use monoclonal antibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52) that cause profound and long-lasting immunosuppression. Emerging data indicate that HBV reactivation could al...
متن کاملAssociation between ABO blood group and hepatitis B and C infection
Background: Hepatitis is among the major health problems, especially in developing countries. During past decades, the association between type of blood group (ABO) and hepatitis B and C virus has always been discussed. This study was designed to investigate the possible association between type of ABO blood group and chronic hepatitis B and C infection. Methods: In the present analytical stud...
متن کاملHepatitis B and Hepatitis C in large vehicle drivers in center of Iran (Yazd)
Introduction: Hepatitis B and C are major health problems in many countries, especially developing areas. The frequency of hepatitis B is less than 0.8%, and chronic hepatitis C is less than 0.5% in the general population of Yazd in the center of Iran. Large vehicle drivers have some risk factors for acquiring hepatitis B and C infection. This is important because viral hepatitis complications,...
متن کاملFrequency of Torque Teno Mini Virus in Hepatitis B and C Patients and Healthy Blood Donors in Isfahan, Iran
Background: Recently, some new viruses have been identified for their association with hepatitis which Torque Teno Mini Virus being among them. The aim of this study was to determine the frequency of Torque Teno Mini Virus in healthy individuals and hepatitis B and C patients in Isfahan, Iran. Materials and Methods: One hundred serum samples of healthy individuals from Isfahan Blood Transfusi...
متن کامل